A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with temozolomide in subjects with anaplastic gliomas or glioblastoma currently stable on a maintenance temozolomide dose
Assessed at each visit/periodic visits
Yes
Clinical Sciences & Operations
Study Director
Sanofi
United States: Food and Drug Administration
TED11441
NCT00704080
August 2008
February 2013
Name | Location |
---|---|
Investigational Site Number | Los Angeles, California 90033 |
Investigational Site Number | Birmingham, Alabama 35205 |
Investigational Site Number | Boston, Massachusetts 02115 |
Investigational Site Number | New York, New York 10021 |
Investigational Site Number | Cleveland, Ohio 44195 |